EpiPen, a five-inch-long injector that delivers an anti-allergy drug, has become the lightning rod for accusations of corporate greed and price-gouging, and the target of a large social media outpouring by users and their parents. Mylan, the Dutch-American maker of EpiPens, has spurred the criticism for increasing prices by more than 450% over the past decade to more than 0 for each dual-pack, with most of that increase coming in the last two years. The public ire against Mylan has gained political overtones in the Presidential election campaigns and an assured berth in a future Congressional probe, while an online petition to lawmakers has thus far collected more than 127,000 signatures. Greed seems to be the main driver for Mylan extracting higher prices for its near-monopoly device, and the newly expanded insurance coverage for prescription drugs created the enabling market opportunity, says Mark Pauly , Wharton professor of health care management, and business economics and public policy.…